Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
27 Apr 2020
Long-term use of brivaracetam as an adjunctive treatment is well tolerated and effective in patients with focal seizures or primary generalized seizures, as shown in a study.
01 Apr 2019
Perampanel is safe and effective for treating refractory focal seizures in both Asian and non‐Asian populations, a study has found.
Elvira Manzano, 20 Jun 2018
A higher proportion of patients with systemic lupus erythematosus (SLE) experienced improvements in joint and skin symptoms with baricitinib 4 mg once daily vs placebo in a phase II randomized, double-blind, global study.

Tapinarof proven safe, effective for psoriasis in phase II trial

11 Mar 2019
From the survey conducted, it is found that more than 80% of patients with psoriasis have experienced discrimination or humiliation across the world.

A phase II study has shown the efficacy and safety of tapinarof cream in adult patients with psoriasis.

The investigators assessed the safety and efficacy of tapinarof in a new cream formulation at two concentrations and with two application frequencies in this double-blind, vehicle-controlled, randomized, six-arm trial. Participants included adults with psoriasis with body surface involvement ≥1 percent and ≤15 percent and Physician Global Assessment (PGA) score ≥2 at baseline.

PGA of 0 or 1 at week 12 and a 2-grade improvement from baseline were the primary endpoints. Further analyses included assessment of ≥75-percent improvement of Psoriasis Area and Severity Index (PASI) and mean percent change in PASI and body surface area involvement.

Patients in the tapinarof groups had statistically significantly higher (at a 0.05 significance level) treatment success, defined by PGA 0 or 1 and a 2-grade improvement at week 12 (65 percent [1% twice daily], 56 percent [1% once daily], 46 percent [0.5% twice daily] and 36 percent [0.5% once daily]) than those in the vehicle groups (11 percent [twice daily] and 5 percent [once daily]).

Treatment success was maintained for 4 weeks post-treatment.

However, patients treated with tapinarof (85/152; 56 percent) were more likely to experience treatment-emergent adverse events (TEAEs) than those in the vehicle group (19/75; 25 percent). TEAEs were mild-to-moderate in intensity. Moreover, severe TEAEs were reported in all tapinarof groups except the 0.5% once-daily group.

Large confirmation trials are warranted, according to the investigators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
27 Apr 2020
Long-term use of brivaracetam as an adjunctive treatment is well tolerated and effective in patients with focal seizures or primary generalized seizures, as shown in a study.
01 Apr 2019
Perampanel is safe and effective for treating refractory focal seizures in both Asian and non‐Asian populations, a study has found.
Elvira Manzano, 20 Jun 2018
A higher proportion of patients with systemic lupus erythematosus (SLE) experienced improvements in joint and skin symptoms with baricitinib 4 mg once daily vs placebo in a phase II randomized, double-blind, global study.